FDA grants fast-track status for Ablynx ’s caplacizumab to treat aTTP

Belgian biopharmaceutical company Ablynx has received fast-track designation from the US Food and Drug Administration (FDA) for its caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (aTTP).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news